Intravenously delivered mesenchymal stem cells

Circulation Research

Volumn 120, Issue 10, 2017, Pages 1598-1613

  Luger, Dror ^a   Lipinski, Michael J ^a   Westman, Peter C ^a   Glover, David K ^b   Dimastromatteo, Julien ^b   Frias, Juan C ^c   Albelda, M Teresa ^d   Sikora, Sergey ^e   Kharazi, Alex ^e   Vertelov, Grigory ^e   Waksman, Ron ^a   Epstein, Stephen E ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^d INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^e Cardiocell Inc   (United States)

Author keywords

cardiomyopathies; inflammation; killer cells, natural; myocardial infarction; stem cells

Indexed keywords

SODIUM CHLORIDE; TRIPHENYLTETRAZOLIUM;

ACUTE HEART INFARCTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HUMAN; HUMAN CELL; ISCHEMIC CARDIOMYOPATHY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; STAINING; ANIMAL; CARDIOMYOPATHIES; CELL CULTURE; HEART LEFT VENTRICLE FUNCTION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MESENCHYMAL STROMA CELL; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ANIMALS; CARDIOMYOPATHIES; CELLS, CULTURED; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85014056957     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.310599     Document Type: Article

References (63)

1. Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, Epstein SE, Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction. J Am Coll Cardiol 2016 67 2050 2060. doi: 10.1016/j.jacc.2016.01.073.
2. Zheng G, Ge M, Qiu G, Shu Q, Xu J, Mesenchymal stromal cells affect disease outcomes via macrophage polarization. Stem Cells Int 2015 2015 989473. doi: 10.1155/2015/989473.
3. Saxena A, Russo I, Frangogiannis NG, Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res 2016 167 152 166. doi: 10.1016/j.trsl.2015.07.002.
4. Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DP, The innate immune response in reperfused myocardium. Cardiovasc Res 2012 94 276 283. doi: 10.1093/cvr/cvs018.
5. Vinten-Johansen J, Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004 61 481 497. doi: 10.1016/j.cardiores.2003.10.011.
6. Gebler A, Zabel O, Seliger B, The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 2012 18 128 134. doi: 10.1016/j.molmed.2011.10.004.
7. van den Akker F, de Jager SC, Sluijter JP, Mesenchymal stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors. Mediators Inflamm 2013 2013 181020. doi: 10.1155/2013/181020.
8. Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, Kyurkchiev S, Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells 2014 6 552 570. doi: 10.4252/wjsc.v6.i5.552.
9. Kinnaird T, Stabile E, Burnett MS, Epstein SE, Bone-marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res 2004 95 354 363. doi: 10.1161/01.RES.0000137878.26174.66.
10. Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE, Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004 94 678 685. doi: 10.1161/01.RES.0000118601.37875.AC.
11. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H, Noiseux N, Zhang L, Pratt RE, Ingwall JS, Dzau VJ, Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005 11 367 368. doi: 10.1038/nm0405-367.
12. Gnecchi M, Zhang Z, Ni A, Dzau VJ, Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res 2008 103 1204 1219. doi: 10.1161/CIRCRESAHA.108.176826.
13. Takahashi M, Li TS, Suzuki R, Kobayashi T, Ito H, Ikeda Y, Matsuzaki M, Hamano K, Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 2006 291 H886 H893. doi: 10.1152/ajpheart.00142.2006.
14. Malliaras K, Li TS, Luthringer D, Terrovitis J, Cheng K, Chakravarty T, Galang G, Zhang Y, Schoenhoff F, Van Eyk J, Marbán L, Marbán E, Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012 125 100 112. doi: 10.1161/CIRCULATIONAHA.111.042598.
15. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W, A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009 54 2277 2286. doi: 10.1016/j.jacc.2009.06.055.
16. Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, Yamagishi M, Mori H, Kangawa K, Kitamura S, Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol 2004 287 H2670 H2676. doi: 10.1152/ajpheart.01071.2003.
17. Jiang W, Ma A, Wang T, Han K, Liu Y, Zhang Y, Zhao X, Dong A, Du Y, Huang X, Wang J, Lei X, Zheng X, Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. Transpl Int 2006 19 570 580. doi: 10.1111/j.1432-2277.2006.00307.x.
18. Karantalis V, Hare JM, Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015 116 1413 1430. doi: 10.1161/CIRCRESAHA.116.303614.
19. Kim J, Shapiro L, Flynn A, The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease. Pharmacol Ther 2015 151 8 15. doi: 10.1016/j.pharmthera.2015.02.003.
20. Lee ST, White AJ, Matsushita S, Malliaras K, Steenbergen C, Zhang Y, Li TS, Terrovitis J, Yee K, Simsir S, Makkar R, Marbán E, Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol 2011 57 455 465. doi: 10.1016/j.jacc.2010.07.049.
21. Smith RR, Barile L, Cho HC, Leppo MK, Hare JM, Messina E, Giacomello A, Abraham MR, Marbán E, Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007 115 896 908. doi: 10.1161/CIRCULATIONAHA.106.655209.
22. Yee K, Malliaras K, Kanazawa H, Allogeneic cardiospheres delivered via percutaneous transendocardial injection increase viable myocardium, decrease scar size, and attenuate cardiac dilatation in porcine ischemic cardiomyopathy. PLoS One 2014 9 e113805. doi: 10.1371/journal.pone.0113805.
23. Maslov LN, Podoksenov IK, Portnichenko AG, Naumova AV, [Hypoxic preconditioning of stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction]. Vestn Ross Akad Med Nauk 2013 16 25
24. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, Sun T, Kishore R, Phillips MI, Losordo DW, Qin G, Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res 2009 104 1209 1216. doi: 10.1161/CIRCRESAHA.109.197723.
25. Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA, Neutrophils-A key component of ischemia-reperfusion injury. Shock 2013 40 463 470. doi: 10.1097/SHK.0000000000000044.
26. Carbone F, Nencioni A, Mach F, Vuilleumier N, Montecucco F, Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013 110 501 514. doi: 10.1160/TH13-03-0211.
27. Costantini C, Micheletti A, Calzetti F, Perbellini O, Pizzolo G, Cassatella MA, Neutrophil activation and survival are modulated by interaction with NK cells. Int Immunol 2010 22 827 838. doi: 10.1093/intimm/dxq434.
28. Dayan V, Yannarelli G, Billia F, Filomeno P, Wang XH, Davies JE, Keating A, Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res Cardiol 2011 106 1299 1310. doi: 10.1007/s00395-011-0221-9.
29. Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, Dawn B, Adult bone marrow cell therapy for ischemic heart disease: evidence and insights from randomized controlled trials. Circ Res 2015 117 558 575. doi: 10.1161/CIRCRESAHA.114.304792.
30. Rosen MR, Myerburg RJ, Francis DP, Cole GD, Marbán E, Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement. J Am Coll Cardiol 2014 64 922 937. doi: 10.1016/j.jacc.2014.06.1175.
31. White IA, Sanina C, Balkan W, Hare JM, Mesenchymal stem cells in cardiology. Methods Mol Biol 2016 1416 55 87. doi: 10.1007/978-1-4939-3584-0-4.
32. Liu J, Wang H, Li J, Inflammation and inflammatory cells in myocardial infarction and reperfusion injury: a double-edged sword. Clin Med Insights Cardiol 2016 10 79 84. doi: 10.4137/CMC.S33164.
33. Caplan AI, Dennis JE, Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006 98 1076 1084. doi: 10.1002/jcb.20886.
34. Kelkar AA, Butler J, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun W, Luger D, Epstein SE, Mechanisms contributing to the progression of ischemic and nonischemic dilated cardiomyopathy: possible modulating effects of paracrine activities of stem cells. J Am Coll Cardiol 2015 66 2038 2047. doi: 10.1016/j.jacc.2015.09.010.
35. Bernardo ME, Fibbe WE, Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell 2013 13 392 402. doi: 10.1016/j.stem.2013.09.006.
36. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P, Prockop DJ, Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009 5 54 63. doi: 10.1016/j.stem.2009.05.003.
37. Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A, Miller L, Guetta E, Zipori D, Kedes LH, Kloner RA, Leor J, Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation 2003 108 863 868. doi: 10.1161/01.CIR.0000084828.50310.6A.
38. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ, Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009 325 612 616. doi: 10.1126/science.1175202.
39. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD, Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res 2014 114 266 282. doi: 10.1161/CIRCRESAHA.113.301720.
40. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M, Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006 24 74 85. doi: 10.1634/stemcells.2004-0359.
41. Lankester AC, Ball LM, Lang P, Handgretinger R, Immunotherapy in the context of hematopoietic stem cell transplantation: the emerging role of natural killer cells and mesenchymal stromal cells. Pediatr Clin North Am 2010 57 97 121. doi: 10.1016/j.pcl.2009.12.001.
42. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L, Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008 111 1327 1333. doi: 10.1182/blood-2007-02-074997.
43. Li T, Zhang Q, Jiang Y, Yu J, Hu Y, Mou T, Chen G, Li G, Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. Oncoimmunology 2016 5 e1069936. doi: 10.1080/2162402X.2015.1069936.
44. Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A, Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res 2014 20 4096 4106. doi: 10.1158/1078-0432.CCR-14-0635.
45. Ong S, Rose NR, Čiháková D, Natural killer cells in inflammatory heart disease. Clin Immunol 2017 175 26 33. doi: 10.1016/j.clim.2016.11.010.
46. Yan X, Hegab AE, Endo J, Anzai A, Matsuhashi T, Katsumata Y, Ito K, Yamamoto T, Betsuyaku T, Shinmura K, Shen W, Vivier E, Fukuda K, Sano M, Lung natural killer cells play a major counter-regulatory role in pulmonary vascular hyperpermeability after myocardial infarction. Circ Res 2014 114 637 649. doi: 10.1161/CIRCRESAHA.114.302625.
47. Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M, Weber C, Soehnlein O, Steffens S, Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. Eur Heart J 2016
48. Saiwai H, Kumamaru H, Ohkawa Y, Kubota K, Kobayakawa K, Yamada H, Yokomizo T, Iwamoto Y, Okada S, Ly6C+ Ly6G-Myeloid-derived suppressor cells play a critical role in the resolution of acute inflammation and the subsequent tissue repair process after spinal cord injury. J Neurochem 2013 125 74 88. doi: 10.1111/jnc.12135.
49. Swirski FK, Nahrendorf M, Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013 339 161 166. doi: 10.1126/science.1230719.
50. Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P, van der Laan AM, van der Lahn AM, Swirski FK, Weissleder R, Nahrendorf M, Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res 2014 115 284 295. doi: 10.1161/CIRCRESAHA.115.303567.
51. Shiraishi M, Shintani Y, Shintani Y, Ishida H, Saba R, Yamaguchi A, Adachi H, Yashiro K, Suzuki K, Alternatively activated macrophages determine repair of the infarcted adult murine heart. J Clin Invest 2016 126 2151 2166. doi: 10.1172/JCI85782.
52. de Couto G, Liu W, Tseliou E, Sun B, Makkar N, Kanazawa H, Arditi M, Marbán E, Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction. J Clin Invest 2015 125 3147 3162. doi: 10.1172/JCI81321.
53. Prabhu SD, Frangogiannis NG, The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res 2016 119 91 112. doi: 10.1161/CIRCRESAHA.116.303577.
54. Ben-Mordechai T, Holbova R, Landa-Rouben N, Harel-Adar T, Feinberg MS, Abd Elrahman I, Blum G, Epstein FH, Silman Z, Cohen S, Leor J, Macrophage subpopulations are essential for infarct repair with and without stem cell therapy. J Am Coll Cardiol 2013 62 1890 1901. doi: 10.1016/j.jacc.2013.07.057.
55. Horne BD, Anderson JL, John JM, Weaver A, Bair TL, Jensen KR, Renlund DG, Muhlestein JB, Intermountain Heart Collaborative Study Group Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol 2005 45 1638 1643. doi: 10.1016/j.jacc.2005.02.054.
56. Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M, Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-A randomized trial. Circ Res 2017 120 332 340. doi: 10.1161/CIRCRESAHA.116.309717.
57. Emami H, Singh P, MacNabb M, Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 2015 8 121 130. doi: 10.1016/j.jcmg.2014.10.009.
58. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-Alpha, in patients with moderate-To-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003 107 3133 3140. doi: 10.1161/01.CIR.0000077913.60364.D2.
59. Deftereos S, Giannopoulos G, Panagopoulou V, Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail 2014 2 131 137. doi: 10.1016/j.jchf.2013.11.006.
60. Ankrum JA, Ong JF, Karp JM, Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014 32 252 260. doi: 10.1038/nbt.2816.
61. Li J, Ezzelarab MB, Cooper DK, Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation. Xenotransplantation 2012 19 273 285. doi: 10.1111/xen.12000.
62. Chinnadurai R, Ng S, Velu V, Galipeau J, Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel disease. World J Gastroenterol 2015 21 4779 4787. doi: 10.3748/wjg.v21.i16.4779.
63. Paul A, Srivastava S, Chen G, Shum-Tim D, Prakash S, Functional assessment of adipose stem cells for xenotransplantation using myocardial infarction immunocompetent models: comparison with bone marrow stem cells. Cell Biochem Biophys 2013 67 263 273. doi: 10.1007/s12013-011-9323-0.